FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2143723493> ?p ?o ?g. }

• W2143723493 endingPage "6386" @default.
• W2143723493 startingPage "6375" @default.
• W2143723493 abstract "// Ross M. Drayton 1 , Stefan Peter 1 , Katie Myers 1 , Saiful Miah 1,2 , Ewa Dudziec 1,2 Helen E. Bryant 1 and James W. F. Catto 1,2 1 Academic Unit of Molecular Oncology, University of Sheffield, UK 2 Academic Urology Unit, University of Sheffield, UK Correspondence: James Catto, email: // Keywords : FOXA1, Urothelial cancer, Bladder cancer, FGFR3 Received : July 4, 2014 Accepted : July 13, 2014 Published : July 15, 2014 Abstract Urothelial cell carcinoma of the bladder (UCC) is a common disease often characterized by FGFR3 dysregulation. Whilst upregulation of this oncogene occurs most frequently in low-grade non-invasive tumors, recent data reveal increased FGFR3 expression characterizes a common sub-type of invasive UCC sharing molecular similarities with breast cancer. These similarities include upregulation of the FOXA1 transcription factor and reduced expression of microRNAs-99a/100. We have previously identified direct regulation of FGFR3 by these two microRNAs and now search for further targets. Using a microarray meta-database we find potential FOXA1 regulation by microRNAs-99a/100. We confirm direct targeting of the FOXA1 3’UTR by microRNAs-99a/100 and also potential indirect regulation through microRNA-485-5p/SOX5/JUN-D/FOXL1 and microRNA-486/FOXO1a. In 292 benign and malignant urothelial samples, we find an inverse correlation between the expression of FOXA1 and microRNAs-99a/100 (r=-0.33 to -0.43, p<0.05). As for FGFR3 in UCC, tumors with high FOXA1 expression have lower rates of progression than those with low expression (Log rank p=0.009). Using global gene expression and CpG methylation profiling we find genotypic consequences of FOXA1 upregulation in UCC. Genetic changes are associated with regional hypomethylation, occur near FOXA1 binding sites, and mirror gene expression changes previously reported in FGFR3 mutant-UCC. These include gene silencing through aberrant hypermethylation (e.g. IGFBP3) and affect genes characterizing breast cancer sub-types (e.g. ERBB2). In conclusion, we have identified microRNAs-99a/100 mediate a direct relationship between FGFR3 and FOXA1 and potentially facilitate cross talk between these pathways in UCC." @default.
• W2143723493 created "2016-06-24" @default.
• W2143723493 creator A5001256089 @default.
• W2143723493 creator A5009489489 @default.
• W2143723493 creator A5010798475 @default.
• W2143723493 creator A5032231578 @default.
• W2143723493 creator A5036556349 @default.
• W2143723493 creator A5049287151 @default.
• W2143723493 creator A5059215689 @default.
• W2143723493 date "2014-07-15" @default.
• W2143723493 modified "2023-10-03" @default.
• W2143723493 title "MicroRNA-99a and 100 mediated upregulation of FOXA1 in bladder cancer" @default.
• W2143723493 cites W1966498224 @default.
• W2143723493 cites W1972240152 @default.
• W2143723493 cites W1976979840 @default.
• W2143723493 cites W1993876923 @default.
• W2143723493 cites W2002262418 @default.
• W2143723493 cites W2022188526 @default.
• W2143723493 cites W2033775272 @default.
• W2143723493 cites W2043262665 @default.
• W2143723493 cites W2049108030 @default.
• W2143723493 cites W2051762085 @default.
• W2143723493 cites W2056762101 @default.
• W2143723493 cites W2061035319 @default.
• W2143723493 cites W2061086491 @default.
• W2143723493 cites W2066787077 @default.
• W2143723493 cites W2067964015 @default.
• W2143723493 cites W2068523052 @default.
• W2143723493 cites W2074755242 @default.
• W2143723493 cites W2080621653 @default.
• W2143723493 cites W2096477951 @default.
• W2143723493 cites W2098211567 @default.
• W2143723493 cites W2099951161 @default.
• W2143723493 cites W2100812557 @default.
• W2143723493 cites W2113235293 @default.
• W2143723493 cites W2114698467 @default.
• W2143723493 cites W2117490187 @default.
• W2143723493 cites W2119938419 @default.
• W2143723493 cites W2129430629 @default.
• W2143723493 cites W2150629758 @default.
• W2143723493 cites W2154688988 @default.
• W2143723493 cites W2155781648 @default.
• W2143723493 cites W2156662494 @default.
• W2143723493 cites W2157968886 @default.
• W2143723493 cites W2159183769 @default.
• W2143723493 cites W2159228663 @default.
• W2143723493 cites W2159602607 @default.
• W2143723493 cites W2160975559 @default.
• W2143723493 cites W2165662398 @default.
• W2143723493 cites W2166037178 @default.
• W2143723493 cites W2168241534 @default.
• W2143723493 cites W4294107304 @default.
• W2143723493 doi "https://doi.org/10.18632/oncotarget.2221" @default.
• W2143723493 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4171637" @default.
• W2143723493 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25071007" @default.
• W2143723493 hasPublicationYear "2014" @default.
• W2143723493 type Work @default.
• W2143723493 sameAs 2143723493 @default.
• W2143723493 citedByCount "22" @default.
• W2143723493 countsByYear W21437234932014 @default.
• W2143723493 countsByYear W21437234932015 @default.
• W2143723493 countsByYear W21437234932016 @default.
• W2143723493 countsByYear W21437234932017 @default.
• W2143723493 countsByYear W21437234932018 @default.
• W2143723493 countsByYear W21437234932019 @default.
• W2143723493 countsByYear W21437234932020 @default.
• W2143723493 countsByYear W21437234932021 @default.
• W2143723493 crossrefType "journal-article" @default.
• W2143723493 hasAuthorship W2143723493A5001256089 @default.
• W2143723493 hasAuthorship W2143723493A5009489489 @default.
• W2143723493 hasAuthorship W2143723493A5010798475 @default.
• W2143723493 hasAuthorship W2143723493A5032231578 @default.
• W2143723493 hasAuthorship W2143723493A5036556349 @default.
• W2143723493 hasAuthorship W2143723493A5049287151 @default.
• W2143723493 hasAuthorship W2143723493A5059215689 @default.
• W2143723493 hasBestOaLocation W21437234931 @default.
• W2143723493 hasConcept C104317684 @default.
• W2143723493 hasConcept C121608353 @default.
• W2143723493 hasConcept C126322002 @default.
• W2143723493 hasConcept C127561419 @default.
• W2143723493 hasConcept C143998085 @default.
• W2143723493 hasConcept C145059251 @default.
• W2143723493 hasConcept C154456304 @default.
• W2143723493 hasConcept C2780352672 @default.
• W2143723493 hasConcept C2781018059 @default.
• W2143723493 hasConcept C29537977 @default.
• W2143723493 hasConcept C502942594 @default.
• W2143723493 hasConcept C530470458 @default.
• W2143723493 hasConcept C54355233 @default.
• W2143723493 hasConcept C71924100 @default.
• W2143723493 hasConcept C86803240 @default.
• W2143723493 hasConceptScore W2143723493C104317684 @default.
• W2143723493 hasConceptScore W2143723493C121608353 @default.
• W2143723493 hasConceptScore W2143723493C126322002 @default.
• W2143723493 hasConceptScore W2143723493C127561419 @default.
• W2143723493 hasConceptScore W2143723493C143998085 @default.
• W2143723493 hasConceptScore W2143723493C145059251 @default.
• W2143723493 hasConceptScore W2143723493C154456304 @default.

• next